Vancomycin-Resistant Enterococcus Faecium Infections Market Size, Share, Regional Outlook, Competitive Strategies And Fo

1. Hexa Reports Market Research Reports and Insightful Company Profiles Global Vancomycin-Resistant Enterococcus Faecium Infections Industry 2015 Market Share, Size, Industry Profile, Market Prize, Forecast and Overview Global Markets Direct's, 'Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2015', provides an overview of the Vancomycin-Resistant Enterococcus Faecium Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Vancomycin- Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects. Browse Detail Report With TOC @http://www.hexareports.com/report/vancomycin-resistant- enterococcus-faecium-infections-pipeline-review-h1-2015/details Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the

2. Hexa Reports Market Research Reports and Insightful Company Profiles profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus Faecium Infections The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Vancomycin- Resistant Enterococcus Faecium Infections and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Vancomycin-Resistant Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre- registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Vancomycin-Resistant Enterococcus Faecium Infections pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter- strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus Faecium Infections

3. Hexa Reports Market Research Reports and Insightful Company Profiles Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Request A Sample copy of This Report @ http://www.hexareports.com/sample/47458 Table Of Content Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Vancomycin-Resistant Enterococcus Faecium Infections Overview 9 Therapeutics Development 10 Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections - Overview 10 Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections - Comparative Analysis 11 Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics under Development by Companies 12 Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics under Investigation by Universities/Institutes 14 Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Products Glance 15 Clinical Stage Products 15 Early Stage Products 16 Vancomycin-Resistant Enterococcus Faecium Infections - Products under Development by Companies 17 Vancomycin-Resistant Enterococcus Faecium Infections - Products under Investigation by Universities/Institutes 19 Vancomycin-Resistant Enterococcus Faecium Infections - Companies Involved in Therapeutics Development 20 Alchemia Limited 20 Alvogen, Inc. 21 Aphios Corporation 22 Cellceutix Corporation 23 Enanta Pharmaceuticals, Inc. 24 Helix BioMedix, Inc. 25 LegoChem Biosciences, Inc 26 Lytix Biopharma AS 27

4. Hexa Reports Market Research Reports and Insightful Company Profiles MGB Biopharma Limited 28 Microbiotix, Inc. 29 MicuRx Pharmaceuticals, Inc. 30 Nabriva Therapeutics AG 31 NovaBay Pharmaceuticals, Inc. 32 NovoBiotic Pharmaceuticals, LLC 33 Oragenics, Inc. 34 Sealife PHARMA GMBH 35 Sentinella Pharmaceuticals, Inc. 36 TAXIS Pharmaceuticals, Inc. 37 Wockhardt Limited 38 Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Target 40 Assessment by Mechanism of Action 42 Assessment by Route of Administration 44 Assessment by Molecule Type 46 Drug Profiles 48 Browse Full Report @ http://www.hexareports.com/report/vancomycin-resistant-enterococcus- faecium-infections-pipeline-review-h1-2015/details About Us: Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Information: Ryan Shaw Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, United States Phone Number 1-800-489-3075 Email Us: sales@hexareports.com Our Website: http://www.hexareports.com/ Our Blogs: http://hexareports.blogspot.in